The Latest Cardiac and Vascular News
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced today the upsize and pricing of its initial public offering of 7,000,000 shares of its common stock […]
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the first clinical procedure with the company’s new lead implantation approach. The novel ultrasound-guided technique is the latest advancement of CVRx’s Barostim™ Baroreflex Activation […]
Paul Verrastro Named CMO and Thomas Hengsteler Named VP of European Sales and Marketing MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding its senior leadership team by adding two medical […]
Incremental Reimbursement in Outpatient Setting Will Expand Availability of the Breakthrough BAROSTIM Therapy Heart Failure Treatment MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for Medicare and Medicaid Services (CMS) granted […]
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) — CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term growth plan. Jared Oasheim, who joined CVRx in 2015, was promoted from Vice President of Finance to Chief Financial Officer (CFO). He […]
CVRx Enrolls the First Patient in a Post Market Heart Failure Registry MINNEAPOLIS, July 21, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced that the BeAT-HF phase III randomized clinical trial has completed enrollment in the post-market phase. CVRx has also enrolled the first patient in a heart failure (“HF”) […]
Offering Will Support US Commercialization of BAROSTIM NEOTM MINNEAPOLIS, July 7, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company with a novel technology that treats patients suffering from chronic heart failure (“HF”) and resistant hypertension, announced today that it raised $50 million to close its latest round of equity financing. Proceeds from the […]
BAROSTIM NEO™ is the World’s First Heart Failure Neuromodulation Device MINNEAPOLIS, June 30, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”). Results from the trial were used […]
BeAT-HF Trial Results Presented as Late-Breaking Clinical Science at ESC Heart Failure 2020 Meeting MINNEAPOLIS, June 23, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced new BeAT-HF trial results from late-breaking clinical science presented virtually at the European Society of Cardiology Heart Failure 2020 Scientific Sessions. The BAROSTIM NEO […]
